James Crapo

James Crapo

Company: BioMimetix

Job title: Chief Executive Officer


BMX-001: New Therapy Showing Increased Survival in Newly Diagnosed Glioblastoma 12:15 pm

New drug class – redox-active metallaporphyrins – positioned to transform the efficacy of radiation and chemotherapy in oncology Novel BMX-001 dual action enhances tumor killing while mitigating radiation-induced side-effects Discussion of ongoing randomized, 160 patient, multi-center trialRead more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.